Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from PainReform ( (PRFX) ) is now available.
On October 1, 2025, PainReform Ltd. announced its financial results for the first half of the year, ending June 30, 2025, highlighting the publication of unaudited condensed financial statements and an operating and financial review. Additionally, the company experienced a change in its board of directors, with Professor Eli Hazum resigning for personal reasons and Asaf Shavit, an experienced financial advisor, being appointed as his replacement. This leadership change is expected to bring valuable expertise to the company’s strategic financial planning.
The most recent analyst rating on (PRFX) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Underperform.
PainReform faces substantial financial hurdles, primarily due to its lack of revenue and persistent losses, making its financial performance the most significant negative factor. Technical analysis reflects a neutral to slightly bearish outlook, while valuation metrics underscore the company’s financial struggles with a negative P/E ratio. Overall, the stock presents high risks without notable strengths to offset these concerns.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PainReform Ltd. is a company involved in the pharmaceutical industry, focusing on the development of reformulated pain medications. The company aims to improve the efficacy and safety of existing pain treatments through its proprietary drug delivery technologies.
Average Trading Volume: 2,935,021
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.86M
For detailed information about PRFX stock, go to TipRanks’ Stock Analysis page.